中国实用内科杂志2025，Vol.45Issue(7)：588-592,5.DOI:10.19538/j.nk2025070108
《微生物治疗报告国际规范(PRIM 2024)》解读
Interpret of Preferred Reporting Items for Microbiotherapy Guidelines(PRIM 2024)
摘要
Abstract
In recent years,the research on microbiotherapy(such as fecal microbiota transplantation,probiotics,phage therapy,oncolytic bacteria,oncolytic viruses,etc.)for diseases has been increasing.However,due to the lack of a unified reporting guideline,many studies have failed to cover all the necessary reporting items required by medical practitioners,researchers,and readers,thereby hindering result reproducibility,safety evaluation,and technological implementation.In 2024,an international multidisciplinary panel of clinical experts from eight countries established the Preferred Reporting Items for Microbiotherapy(PRIM 2024)international guidelines through a Delphi consensus procedure.The PRIM 2024 guidelines included 10 statements and 18 points on diagnosis,delivery route,source,classification,preparation,dosage,state,concomitant treatment,efficacy,and safety.This article introduces and interprets the core components of the guidelines,aiming to provide methodological guidance for clinical research report and establish a foundational framework and reference for standardizing diagnosis and treatment practice in microbiota medicine.关键词
微生物/微生物治疗/微生态医学/指南/规范/标准Key words
microbe/microbiotherapy/microbiota medicine/guideline/specification/standard分类
医药卫生引用本文复制引用
张祖伦,吴霞,崔伯塔,张发明..《微生物治疗报告国际规范(PRIM 2024)》解读[J].中国实用内科杂志,2025,45(7):588-592,5.基金项目
科技部国家重点研发计划(2021YFA0717000) （2021YFA0717000）
国家自然科学基金(82170563) （82170563）
南京医科大学樊代明整合医学研究基金(2020-3) （2020-3）
